Actively Recruiting
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-15
300
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Identify any significant differences in terms of drug response and survival between the different possible alterations in the BRCA1/2 genes, in order to stratify ovarian cancer patients with a view to increasingly personalised and thus effective therapy.
CONDITIONS
Official Title
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with ovarian cancer by December 31, 2021
- Completed BRCA testing at the Medical Genetics Unit of IRCCS AOU Bologna Policlinico S. Orsola by December 31, 2021
- Received follow-up and/or treatment at the Medical Oncology or Gynaecological Oncology departments of IRCCS AOU Bologna for at least 6 months and up to 1 year by December 31, 2021
You will not qualify if you...
- Diagnosis of mucinous or borderline ovarian carcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, Italy, 40138
Actively Recruiting
Research Team
D
Daniela Turchetti, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here